The UGOT IPMS p‐tau217, which simultaneously quantifies multiple p‐tau isoforms,14 Fujirebio Lumipulse G p‐tau217, a fully‐automated chemiluminescent method, and the Lilly MSD p‐tau217,38 a manual electrochemiluminescence method each provided a >5‐fold median increase in the AD pathology group. The gene discussed is MAPT; the disease is Alzheimer disease.